Trials / Completed
CompletedNCT02172963
A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Karolinska Institutet · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.
Detailed description
Patients with grade 2-4 hemorrhagic cystitis will receive decidual stromal cell therapy at approximately 1-2x10\^6 cells/kg once or at weekly intervals dependent on clinical effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Decidual Stromal Cell therapy | Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10\^6 cells/kg. |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2014-06-24
- Last updated
- 2014-06-24
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02172963. Inclusion in this directory is not an endorsement.